Veteran from Multinational Pharma Giants Joins Abogen Biosciences as President of Preclinical Research

On May 26, Abogen announced via its official WeChat account that Dr. Li Weimin has been appointed as the company's President of Preclinical Research.

Li WeiminDr., Warren Li, has over 20 years of extensive experience in the biopharmaceutical industry, with a global strategic vision and proven R&D management capabilities. He has previously held senior management positions at leading global pharmaceutical companies, including Johnson & Johnson, AstraZeneca, and Takeda. His expertise spans drug discovery, translational medicine, and early clinical development. Dr. Warren Li earned his Ph.D. from the University of Illinois Urbana-Champaign (UIUC) in the United States.

After joining Abogen, Dr. Weimin Li willComprehensive Company ManagementPreclinical-stage R&D strategy and pipeline planning to accelerate the clinical translation of pipeline projects, further driving global innovative breakthroughs in Abogen's RNA therapeutics.

Founded in early 2019, Abogen is an innovative biopharmaceutical company dedicated to the research and development of messenger RNA (mRNA) therapeutics. The company possesses an industry-leading mRNA and nanodelivery technology platform with independent intellectual property rights. As one of the few mRNA therapeutics R&D enterprises in China with end-to-end value chain capabilities, it covers all stages from mRNA design and formulation development to large-scale manufacturing. The company has established a robust product pipeline spanning multiple therapeutic areas, including cancer immunotherapy, autoimmune diseases, and the prevention and treatment of infectious diseases.

Source: Abogen Official WeChat

For specific information, please refer to the official statement of the company.